From Wikipedia, the free encyclopedia
Pharmaceutical compound
LME-54 Other names LME54; LME; Lysergic acid methylethylamide; LA-methylethylamide; N-Ethyl-N-methyllysergamide; N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8β-carboxamide Routes of(6aR,9R)-N-ethyl-N,7-dimethyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CCN(C)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
InChI=1S/C19H23N3O/c1-4-21(2)19(23)13-8-15-14-6-5-7-16-18(14)12(10-20-16)9-17(15)22(3)11-13/h5-8,10,13,17,20H,4,9,11H2,1-3H3/t13-,17-/m1/s1
Key:BROWGWCWLHAXPI-CXAGYDPISA-N
LME-54, or simply LME, also known as lysergic acid methylethylamide or as N-methyl-N-ethyllysergamide, is a serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[2][3][4][5][1] It is the analogue of LSD in which one of the N-ethyl groups has been replaced with an N-methyl group.[2][3][4]
The drug was tested in humans at a dose of 25 μg and was found to produce no effects at this dose in several subjects and to produce weaker effects than a 25 μg dose of LSD in one subject.[1] Higher doses do not appear to have been assessed.[1] Based on these findings, LME-54 has been described as weakly active or active but less so than LSD with no specific numbers available.[2][3][4][5][6][7] Its antiserotonergic activity in vitro does not appear to have been reported.[6]
LME-54 was first described in the scientific literature by Harold Alexander Abramson and Andre Rolo by 1965.[1][8]
Table 2. Relative potency values for lysergic acid amides. [...]
TABLE 2. Relative human potency of lysergic acid amides [...]
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4